Peptide-lipid conjugates

US6087325A · kind A · utility

Assignee

• The Liposome Company, Inc. · US

Inventors

• Paul R. Meers · Princeton Junction, US
• Charles Y. C. Pak · Plainsboro, US
• Shaukat Ali · Monmouth Junction, US
• Andrew S. Janoff · Yardley, US
• J. Craig Franklin · Princeton, US
• Ravi K. Erukulla · Plainsboro, US
• Donna Cabral-Lilly · Princeton, US

Key dates

• Filing date: Oct 15, 1997
• Grant date: Jul 11, 2000
• Expiry date: Oct 15, 2017

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.